Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-23
DOI
https://doi.org/10.1200/jco.24.01119
Citations
5
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
7.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Atsushi Takeno, Hisato Kawakami, Narikazu Boku, Kentaro Sawada et al.
5 citations
Journal of Clinical Oncology
Gastric Cancer Management and Outcomes
7.59
article

Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial

Atsushi Takeno, Hisato Kawakami, Narikazu Boku, Kentaro Sawada, Masazumi Takahashi, Hiroo Imai, Hironaga Satake, Hiroki Hara, Shigenori Kadowaki, Ryohei Kawabata, Keiko Minashi, Shogen Boku, Taroh Satoh, Toshio Shimokawa, Takeshi Kawakami, Jin Matsuyama, Daisuke Sakai, Yasuhiro Sakamoto, Masato Kataoka
article en
5 citations

Abstract

Adding ramucirumab to irinotecan does not provide a significant advantage in OS over irinotecan alone in patients with AGC who have progressed during ramucirumab-containing chemotherapy.

Journal of Clinical OncologyVol. 43(19)
Kansai Medical University (JP), Wakayama Medical University (JP), Shizuoka Cancer Center (JP), Osaka National Hospital (JP), Tohoku University Hospital (JP), Kushiro Rosai Hospital (JP), Osaki Citizen Hospital (JP), Osaka Rosai Hospital (JP), Chiba Cancer Center (JP), Higashi Osaka City General Hospital (JP), Saitama Cancer Center (JP), Aichi Cancer Center (JP), Yokohama Municipal Citizen's Hospital (JP), National Hospital Organization (JP), Osaka International Cancer Institute (JP), Nagoya Medical Center (JP), Osaka University Hospital (JP), Kobe City Medical Center General Hospital (JP), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 3%
Gastric Cancer Management and Outcomes
7.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.